11718188|t|Scopolamine: new preparations. Reference treatment for death rattle.
11718188|a|(1) The reference symptomatic drug treatment of death rattle is the use of atropinic agents such as scopolamine or atropine. (2) Marketing authorisation has now been granted in France for scopolamine in this indication, both for a subcutaneous preparation and a transdermal patch. (3) The clinical file on subcutaneous scopolamine delivery mainly comprises non comparative data on 200 patients studied prospectively and 196 patients studied retrospectively. (4) The assessment of transdermal scopolamine patches is limited to a few published cases. (5) Available data show the efficacy of scopolamine, when administered after aspiration of the back of the throat. (6) The main adverse effects are neuropsychological (excitation, hallucinations, delirium). (7) In practice, injectable scopolamine is the reference drug for symptomatic treatment of death rattle.
11718188	0	11	Scopolamine	Chemical	MESH:D012601
11718188	55	67	death rattle	Disease	MESH:D003643
11718188	117	129	death rattle	Disease	MESH:D003643
11718188	144	160	atropinic agents	Chemical	-
11718188	169	180	scopolamine	Chemical	MESH:D012601
11718188	184	192	atropine	Chemical	MESH:D001285
11718188	257	268	scopolamine	Chemical	MESH:D012601
11718188	388	399	scopolamine	Chemical	MESH:D012601
11718188	454	462	patients	Species	9606
11718188	493	501	patients	Species	9606
11718188	561	572	scopolamine	Chemical	MESH:D012601
11718188	658	669	scopolamine	Chemical	MESH:D012601
11718188	798	812	hallucinations	Disease	MESH:D006212
11718188	814	822	delirium	Disease	MESH:D003693
11718188	853	864	scopolamine	Chemical	MESH:D012601
11718188	916	928	death rattle	Disease	MESH:D003643
11718188	Negative_Correlation	MESH:D001285	MESH:D003643
11718188	Positive_Correlation	MESH:D012601	MESH:D003693
11718188	Positive_Correlation	MESH:D012601	MESH:D006212
11718188	Negative_Correlation	MESH:D012601	MESH:D003643

